Results of the second interim analysis of the PALLAS study have just been published online in The Lancet Oncology.
Despite the unexpected negative results showing that the addition of palbociclib to endocrine therapy had no effect on invasive disease-free survival (iDFS; i.e. reducing the chance of the cancer coming back, or of dying or getting another cancer) compared to standard of care, PALLAS is a great example of worldwide collaboration between academia and industry to run a huge pivotal clinical trial and advance breast cancer research. It will enable us to know more about the effects of palbociclib in the treatment of patients with hormone receptor-positive (HR+) HER2-negative early breast cancer.
Thousands of physicians, researchers, nurses, administrators and other health care and research professionals in 21 countries around the globe have been working together to make this happen. Moreover, the 5,796 patients enrolled in PALLAS will be followed for at least 10 years, and both clinical data and collected biomaterial build a huge treasure for future translational research.
The PALLAS trial is being conducted collaboratively by several academic-based global research groups. PALLAS is co-sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Alliance Foundation Trials (AFT) as part of a clinical research collaboration with Pfizer (providing study drug and funding) and other study groups, including PrECOG, LLC; NSABP Foundation Inc; and the Breast International Group (BIG).
